Drug Profile

Autologous stem cell therapy - Regeneration Biomedical

Alternative Names: Autologous adipose-derived stem cells - Regeneration Biomedical; RB-ADSC

Latest Information Update: 03 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regeneration Biomedical
Class Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Alzheimer's disease
Research Amyotrophic lateral sclerosis; Multiple sclerosis; Stroke; Traumatic brain injuries

Most Recent Events

31 Jan 2026 Regeneration Biomedical plans a phase Ib extension trial for Alzheimer disease (Intraventricular) in January 2026 (NCT07373067)
05 May 2025 Interim efficacy and adverse event data from a phase I trial in Alzheimer's disease released by Regeneration Biomedical
05 Apr 2025 Efficacy and adverse events data from a phase-I trial in Alzheimer's disease presented at the 77^th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com